| 1 | The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. | 
                        
                | 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | 
                        
                | 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | 
                        
                | 4 | Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7. | 
                        
                | 5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | 
                        
                | 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) | 
                        
                | 7 | Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. | 
                        
                | 8 | Clinical pipeline report, company report or official report of SK BioPhamaceuticals. | 
                        
                | 9 | Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19. | 
                        
                | 10 | Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88. | 
                        
                | 11 | 2011 Pipeline of Anavex. | 
                        
                | 12 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | 
                        
                | 13 | Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45. | 
            
            
                |  |  |  |  |  |  |